D-dimer level influences thromboembolic events in patients with atrial fibrillation

Nozawa, Takashi; Inoue, Hiroshi; Hirai, Tadakazu; Iwasa, Atsushi; Okumura, Ken; Lee, Jong–Dae; Shimizu, Akihiko; Hayano, Motonobu; Yano, Katsusuke

doi:10.1016/j.ijcard.2005.05.049

Cited by 94 publications

(92 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Paroxysmal AF was defined as AF documented electrocardiographically at least once in the preceding 12 months and lasting at least 1 h. The choice of antithrombotic therapy was left for each physician to decide, since the present study was conducted primarily to determine the significance of levels of hemostatic markers in the prediction of subsequent thromboembolic events. 8 Two hundred sixtythree patients received oral anticoagulants with the mean INR being 1.86 at the time of enrollment, and 163 patients received antiplatelet therapy as aspirin or ticlopidine, but 83 patients did not receive any antithrombotic therapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Accumulation of Risk Factors Increases Risk of Thromboembolic Events in Patients With Nonvalvular Atrial Fibrillation

Inoue

Nozawa

Hirai

et al. 2006

Circ J

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…The diagnostic criteria for these thromboembolic events have been reported previously. 7,8 The INR levels at the time of enrollment, within 6 months of the primary end point and at the time of thromboembolic events were analyzed.…”

mentioning

confidence: 99%

Accumulation of Risk Factors Increases Risk of Thromboembolic Events in Patients With Nonvalvular Atrial Fibrillation

Inoue

Nozawa

Hirai

et al. 2006

Circ J

Self Cite

View full text Add to dashboard Cite

“…In comparison with the thromboembolic risk in patients with idiopathic atrial fibrillation, the annual rate is more than 5% in patients with risk factors. 46 The annual rate of thromboembolic risk in idiopathic atrial fibrillation patients without clinical risk was less than 0.7% in a recent Japanese study. 46 However, the necessity for anticoagulation therapy is emphasized for the prevention of thromboembolism.…”

Section: Estimated Number Of Annual Events In Asymptomaticmentioning

confidence: 93%

Is This a Philosophic Issue?

Shimizu

2010

Circ J

Self Cite

View full text Add to dashboard Cite

Brugada syndrome (BS) has an intermittent or concealed type, which can be unmasked by the sodium (Na + )-channel-blocker challenge test. The appropriate risk stratification of patients with a drug-induced Brugada-type electrocardiographic (ECG), especially those without a history of syncope or aborted sudden cardiac death, remains unclear. The prognosis of patients with BS depends on the clinical type, cardiac arrest, syncope or if asymptomatic. The ratio of the asymptomatic group varies from 56.9% to 63.6% and, furthermore, their annual cardiac event rate is relatively lower at 0.24-3.6% compared with the cardiac arrest group. Patients with a druginduced Brugada-type ECG have a poor prognosis if they had a history of ventricular fibrillation (VF) or aborted sudden cardiac death, because their risk becomes similar to that of patients with spontaneous Brugada-type ECG. They have the disturbance of the Na + -channel and the electrophysiologic substrate of VF, proven by the high inducibility of VF by stimulation test even in patients without spontaneous VF. Spontaneous VF will never occur if there is no VF substrate. Implantable cardioverter-defibrillators will certainly protect them, so patients with a drug-induced Brugada-type ECG, even without a history of VF or aborted sudden cardiac death, should be considered to have a poor prognosis. (Circ J 2010; 74: 2455 - 2463

show abstract

“…Обнаруженный в нашей работе нормальный уровень D-димера у пациентов с диагности-рованным тромбозом УЛП может быть обусловлен низ-кой чувствительностью применяемого нами качествен-ного теста. Согласно данным литературы риск тромбоэм-болических осложнений у больных с фибрилляцией предсердий повышается при уровне D-димера ≥150 нг/мл [8]. Применяемый нами тест определяет уровни только ≥250 нг/мл.…”

Section: результатыunclassified

Comparative Efficacy of Enzyme Medication With Thrombolytic Effect in Atrium Thrombosis and Spontaneous Echo-Contrast Phenomenon in Patients With Atrial Fibrillation

Вышлов¹,

Баталов²,

Марков³

et al. 2015

Ross. kardiol. ž.

View full text Add to dashboard Cite

Aim. To assess efficacy of Thrombovazim ® in combination antithrombotic therapy in atrial fibrillation (AF) with intra-atrial clots of spontaneous echo-contrasting found by echocardiography. Material and methods. Totally 28 patients included with persisting atrial fibrillation: 20 with thrombosis of the left atrium appendage and 8 with the phenomenon of spontaneous echo-contrasting of II-III grate in atrium by transesophageal ultrasound contrast study (TEECS). Among patients with left appendage thrombosis there were 15 men and 5 women, mean age 60,3±1,6. Among those with spontaneous echocontrasting -4 men and 4 women, mean age 58,2±1,2. After detecting the thrombus or spontaneous echo-contrasting phenomenon all patients were prescribed Thrombovazim ® in dosage 800U t. i.d. for 7 days with standard warfarin therapy. Results. On the control TEECS at the 8th day of therapy among 20 patients with previously diagnosed left appendage thrombosis in 19 were found the absence of clots. Level of total fibrinogen and soluble fibrin-monomers complexes in Thrombovazim ® intake did not change. In all patients with spontaneous echocontrasting phenomenon after Thrombovazim ® course this phenomenon still existed, so Thrombovazim ® was not effective in this phenomenon elimination. There were no side effects of Thrombovazim ® . Conclusion.In atrial fibrillation patients and thrombus in left atrium appendage the use of Thrombovazim ® 800U t. i.d. per os at the background of standard therapy by warfarin during 7 days in 95% leads to the lysis of clots without side effects. In spontaneous echo-contrasting phenomenon in atrial fibrillation Thrombovazim ® 800U t. i.d. per os with standard therapy for 7 days does not lead to this phenomenon elimination. The lack of effect of Thrombovazim ® in the phenomenon of spontaneous echo-contrasting indirectly suggests that there are not fibrin strands in this phenomenon. Цель. Оценка эффективности применения Тромбовазима ® в комплексной противотромботической терапии больных с фибрилляцией предсердий (ФП) при обнаружении внутрипредсердных тромбов или феномена спонтанного эхоконтрастирования. Материал и методы. В исследование было включено 28 больных с персисти-рующей фибрилляцией предсердий: 20 больных с тромбами в ушке левого предсердия и 8 больных с феноменом спонтанного эхоконтрастирования II-III степени в полости предсердий по данным чреспищеводного ультразвуко-вого исследования сердца (ЧПУЗИ). Среди пациентов с тромбозом ушка левого предсердия было 15 мужчин и 5 женщин, средний возраст составил 60,3±1,6 г. Среди пациентов с феноменом спонтанного эхоконтрастирования: 4 мужчины и 4 женщины, средний возраст -58,2±1,2 г. После обнаружения тромбоза или феномена спонтанного эхоконтрастирования всем больным был назначен Тромбовазим ® в дозе 800 ЕД 3 раза в день в течение 7 дней в соче-тании со стандартной терапией варфарином. Результаты. На контрольном ЧПУЗИ, выполненном на 8-й день терапии среди 20 пациентов с исходно диагностированным тромбозом ушка левого предсердия у 19 больных отмечено отсутств...

show abstract

D-dimer level influences thromboembolic events in patients with atrial fibrillation

Cited by 94 publications

References 20 publications

Accumulation of Risk Factors Increases Risk of Thromboembolic Events in Patients With Nonvalvular Atrial Fibrillation

Accumulation of Risk Factors Increases Risk of Thromboembolic Events in Patients With Nonvalvular Atrial Fibrillation

Is This a Philosophic Issue?

Comparative Efficacy of Enzyme Medication With Thrombolytic Effect in Atrium Thrombosis and Spontaneous Echo-Contrast Phenomenon in Patients With Atrial Fibrillation

Contact Info

Product

Resources

About